SARS-CoV-2 infection and vaccination in patients with pituitary diseases: the experience of a Brazilian reference center
Authors' conclusion
The prevalence of SARS-CoV-2 infection in our cohort was 35.2%, including 14% of moderate and severe cases requiring hospitalization. The vaccination was universal and safe.
Study context
- Population
- Adults with pituitary diseases followed in a Brazilian reference center; 79 women, age 50 ± 15.8 years, tumoral cause in 74.5%, 45.9% on glucocorticoid replacement for ACTH deficiency
- Participants
- 145 adults
- Outcome
- Prevalence and characteristics of SARS-CoV-2 infection; prevalence, efficacy and safety of anti-SARS-CoV-2 vaccination
Methodological detailsobservational, single reference center
- Observational
- Single reference center
Main finding
As reported in the abstract
SARS-CoV-2 infection
- Confirmed SARS-CoV-2 infection
- 51 patients (35.2%)
- Infected before vaccination
- 22
- Mild disease
- 28 (54.9%)
- Moderate disease
- 17 (33.3%)
- Severe disease
- 6 (11.8%)
- Hospitalization indicated
- 7 (14%)
- Vaccinated against COVID-19
- All but one participant
Observational data: associations, not effects.
Further findings
Risk factors for COVID-19 and severity
- Advanced age was a risk factor for COVID-19
- Moderate/severe COVID-19 had higher prevalence of dyslipidemia and longer duration of pituitary disease
Safety
Vaccine adverse events
- Any adverse event
- 60.4%
- Local pain
- 54.0%
- Fever
- 33.3%
- Headache
- 18.4%
- Alopecia
- 1 case
- Persistent fatigue
- 2 cases
Pituitary apoplexy after SARS-CoV-2 infection
- Pituitary apoplexy in a mild case
- 1 case
Original publication
SARS-CoV-2 infection and vaccination in patients with pituitary diseases: the experience of a Brazilian reference center. Pituitary. Published 9 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →